Physician

Chanh Trung Huynh, MD

According to 2025 Medicare claims, Chanh Huynh, MD (NPI: 1134324536) practices hematology/oncology in the York-Hanover, PA market, with the plurality of this provider's patient population coming from York, PA. This provider's primary affiliated billing organization is CANCER CARE ASSOCIATES OF YORK, INC. (NPI: 1578587101; TIN: 232122436) and primary practice location at 17403-5049.

Huynh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 852 traditional Medicare patients, billed 122,857 HCPCS/CPT codes, and received $2,598,603 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,409 prescription claims across 288 beneficiaries totaling $899,704 in drug costs, led by Eliquis (Apixaban). 2023 DME data shows 17 claims. Open Payments data shows 58 records totaling $530,226. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,147,590 and ending at $899,704. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $8,627 to $840.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	910	214,120	$2,543,390
2016	853	232,833	$2,642,102
2017	826	157,387	$2,583,387
2018	827	166,683	$2,457,881
2019	927	194,956	$2,902,533
2020	942	173,611	$2,846,139
2021	959	135,592	$2,672,547
2022	903	142,268	$2,898,741
2023	896	132,300	$2,240,192
2024	852	122,857	$2,598,603

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	265	1,195	$1,147,590
2016	279	1,488	$1,488,308
2017	265	1,183	$734,537
2018	258	1,204	$1,336,484
2019	222	1,017	$599,846
2020	231	1,030	$660,008
2021	230	1,087	$829,805
2022	237	1,135	$701,501
2023	250	1,210	$1,455,154
2024	288	1,409	$899,704

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	86	212	$30,777
2016	91	239	$48,209
2017	99	201	$17,333
2018	101	206	$11,966
2019	N/R	57	$8,051
2020	N/R	28	$3,689
2021	N/R	22	$2,272
2022	N/R	27	$1,309
2023	N/R	17	$1,380
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	293	824	$127
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	336	717	$12
80053	Blood test, comprehensive group of blood chemicals	316	1,321	$10
36415	Insertion of needle into vein for collection of blood sample	409	1,694	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	393	1,581	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	110	5,025	$95,517
Exemestane	Exemestane	20	1,550	$6,395
Enoxaparin Sodium	Enoxaparin Sodium	23	546	$5,913
Anastrozole	Anastrozole	146	10,978	$2,699
Dexamethasone	Dexamethasone	236	2,851	$1,807

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	33	$20,094	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	25	$510,133	BeiGene, Ltd.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Chanh Trung Huynh, MD?

Tedicare shows public-source Medicare data for Chanh Trung Huynh, MD (NPI 1134324536), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Chanh Trung Huynh, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Chanh Trung Huynh, MD?

Chanh Trung Huynh, MD is linked to CANCER CARE ASSOCIATES OF YORK, INC. (billing NPI 1578587101) in the available physician profile data.

Does Chanh Trung Huynh, MD have Open Payments data?

Chanh Trung Huynh, MD has 58 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.